论文部分内容阅读
目的:探究替格瑞洛药物治疗急性冠脉综合征的临床效果。方法:选取2014年12月至2015年12月来该院接受诊治的62例急性冠脉综合征病人作为研究的案例,根据随机数字表法,将其分为探究组和比较组各31例,比较组病人给予氯吡格雷药物治疗,探究组病人给予替格瑞洛药物治疗,对比两组病人疗效。结果:探究组病人给予替格瑞洛药物治疗后,其MACE的发生率只有6.66%,比较组病人给予氯吡格雷药物治疗后,其MACE的发生率高达45.16%,探究组病人在MACE发生率方面,要明显好于比较组(P<0.05)。结论:在急性冠脉综合征的临床治疗中,采用替格瑞洛药物治疗,能够有效地降低病人不良心血管疾病的发生率,减少病人出血情况的发生。
Objective: To investigate the clinical effect of ticagrelor on acute coronary syndrome. Methods: A total of 62 patients with acute coronary syndrome admitted to our hospital from December 2014 to December 2015 were selected as the research cases. According to the random number table method, 31 cases were divided into study group and comparison group, The patients in the comparative group were treated with clopidogrel drug, and the patients in the study group were treated with ticagrelor. The curative effect was compared between the two groups. Results: In the study group, the incidence of MACE was only 6.66% after the drug was given to ticagrelor. The incidence of MACE was 45.16% in the comparison group when treated with clopidogrel. The incidence of MACE in the study group was significantly higher than that of the MACE , It is obviously better than the comparison group (P <0.05). Conclusion: In the clinical treatment of acute coronary syndromes, the use of ticagrelor treatment can effectively reduce the incidence of adverse cardiovascular diseases and reduce the occurrence of bleeding in patients.